Fairvalue-Calculator Fairvalue-Calculator
EN DE

Foghorn Therapeutics Inc (FHTX) Fair Value & Analysis

Healthcare · US · Market cap $244M

Price$4.18
Fair Value$1.84
Upside-56.0%
Quality95/100
Evidence: Low Range $1.38 – $2.30

Fair value as of: Jun 23, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Foghorn Therapeutics Inc (FHTX) currently trades at $4.18, while our model-based Fair Value estimate is $1.84 — implying the stock looks roughly 56.0% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -84% Regeneron Pharmaceuticals, Inc (REGN) +109% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -64%

Frequently asked questions

Is Foghorn Therapeutics Inc (FHTX) undervalued?
As of Jun 23, 2026, our model estimates a fair value of $1.84 versus a price of $4.18 — about −56% (overvalued). Model-based estimate, not financial advice.
What is the fair value of FHTX?
Our 21-model fair value for Foghorn Therapeutics Inc is $1.84 (as of Jun 23, 2026), built from audited fundamentals. The current price is $4.18.
What is the quality score of FHTX?
Foghorn Therapeutics Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.